An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Stopped early · Phase 2

Conditions studied: Generalized Myasthenia Gravis

In brief

The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG)

Key facts

Study ID
NCT03896295
Run by
Momenta Pharmaceuticals, Inc.
People needed
37
Starts
2019-08-06
Expected to finish
2020-12-09
Last updated by the study team
2023-06-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.